A decrease in prostate-specific antigen (PSA) levels is seen in some men with advanced prostate cancer who are treated with Xtandi (enzalutamide).
Levels of PSA in the blood can become elevated when there is a problem with the prostate, such as when prostate cancer develops. Monitoring PSA levels in the blood is one of the methods used to determine how prostate cancer is responding to treatment with Xtandi.